Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer

Conditions:   Carcinoma, Small Cell;   Solid Tumors;   SCLC;   Extrapulmonary Lung Cancer;   Relapse Interventions:   Drug: Topotecan + M6620;   Drug: Topotecan Sponsor:   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

CONCLUSIONS: The combination of BCL2 and Wee1 inhibition presents a novel therapeutic strategy for the treatment of SCNPC. PMID: 31806643 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma. Mol Med Rep. 2019 Nov 05;: Authors: Lv P, Liu Z, Xu B, Tang C, Li X, Qin H, Yang S, Gao H, He K, Liu X Abstract Matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry (MALDI‑TOF‑MS) was employed to analyze differential serum and urine peptides in patients with small cell lung cancer (SCLC) and healthy individuals, and SCLC diagnostic classification models were constructed. Serum and urine samples from 72 patients with SCLC, age‑ and gender...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conclusions: Pre-treatment SUVmax-PT are prognostic factor of OS in non-metastatic SCLC patients undergoing treatment. SUVmax have no prognostic value for survival in metastatic SCLC patients.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: These findings indicate that a majority of EBUS-TBNA specimens provide sufficient tissue for subtyping pulmonary NSCLC and SCLC while performing IHC.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Interventional pulmonology Source Type: research
Conclusions: The endosonography with use of histological 25G core needles is feasible and safe and seems to be a reasonable approach for IHC and MT in advanced LC patients
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Interventional pulmonology Source Type: research
Conditions:   Carcinoma, Small Cell;   Solid Tumors;   SCLC;   Extrapulmonary Lung Cancer;   Relapse Interventions:   Drug: Topotecan + M6620;   Drug: Topotecan Sponsor:   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Pulmonary high-grade neuroendocrine carcinoma includes the following two clinicopathological entities classified on the basis of their morphological and biological features: large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) [1,2]. LCNEC and SCLC share several histological features, including rosette formation, molding of nuclei, and lack of apparent glandular formation and keratinization [3,4]. LCNEC, diagnosed in approximately 3% of all patients with lung cancer, is generally associated with high rate of metastases and poor patient survival [5,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: Genomic subtyping has potentials in prognostication and therapeutic decision-making for patients with LCNEC and cfDNA analysis may be a reliable alternative for genomic profiling of LCNEC. PMID: 31694833 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusion Our personal experience indicated that chemotherapy might provide a survival benefit in SCLC patients with metastasis-induced pancreatitis, especially those with good performance status.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
High-grade neuroendocrine lung malignancies (large-cell neuroendocrine cell carcinoma, LCNEC, and small-cell lung carcinoma, SCLC) are among the most deadly lung cancer conditions with no optimal clinical management. The biological relationships between SCLC and LCNEC are still largely unknown and a current matter of debate as growing molecular data reveal high...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Lung Cancer | Research | Small Cell Lung Cancer